**Product:** LILETTA®

**Company:** Medicines360

**Therapeutic Area & Indication:**
IUD to prevent pregnancy through timed release of hormone levonorgestrel

---

**About the Product**
LILETTA® is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 6 years. It first received FDA approval in 2015 and with the most recent approval in 2019, it was the first hormonal intrauterine device (IUD) to be approved for pregnancy prevention for up to six years.
**PRODUCT:** EVENITY® (romosozumab-aqqg)

**COMPANY:** Amgen

**THERAPEUTIC AREA & INDICATION:**
Osteoporosis in post-menopausal women at high risk of bone fracture

---

**ABOUT THE PRODUCT**

EVENITY® is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. EVENITY® is the only osteoporosis therapy that delivers the dual therapeutic effects of increased bone formation and decreased bone resorption. It also fulfills the long-standing and elusive goal of therapeutically harnessing the very system that the skeleton itself utilizes for rapid bone strengthening. EVENITY® is a registered trademark of Amgen Inc.
**Product:** Aimovig®

**Company:** Amgen

**Therapeutic Area & Indication:**
CGRP receptor blocker
to treat chronic migraine

---

**About the Product**
Aimovig® (erenumab-aooe) is the first approved human monoclonal antibody inhibitor of the calcitonin gene-related peptide (CGRP) receptor, a protein which plays a key role in migraine pathophysiology. Aimovig® is approved for the preventive treatment of migraine in adults, and offers convenient, once-monthly treatment that reduces migraine frequency and acute migraine medication use. Previously available preventive therapies could reduce migraine frequency and symptoms, but were repurposed from other indications. Amgen’s development of Aimovig® culminated following more than a decade-long effort. Aimovig® is a registered trademark of Amgen Inc and Novartis Pharmaceuticals.
**Product:** Emgality® (galcanzumab-gnlm)

**Company:** Eli Lilly and Company

**Therapeutic Area & Indication:**
Once a month CGRP antibody preventive treatment for adult migraine

---

**About the Product**

Emgality® is the only disease-specific anti-calcitonin gene-related peptide (CGRP) antibody approved for two disabling, distinct headache disorders, migraine and episodic cluster headache.

- A high affinity, selective, neutralizing antibody to the CGRP ligand that blocks its binding to the receptor
- The majority of patients with migraine or episodic cluster headache reported clinically meaningful improvements:
  - 60% of patients with episodic migraine achieved a 50% or greater reduction in monthly migraine headache days, and up to 16% reported a 100% response to treatment.
  - 70% of patients with episodic cluster headache reported a 50% or greater reduction in weekly cluster headache attacks.
**PRODUCT:** TREMFYA®

**COMPANY:** Janssen Biotech, Inc.

**THERAPEUTIC AREA & INDICATION:**
Medium to severe plaque psoriasis in adults

---

**ABOUT THE PRODUCT**

TREMFYA is a first-in-class fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor -- an important driver of inflammation in psoriasis and other diseases. TREMFYA is approved in more than 70 countries, to treat adult patients with moderate to severe plaque psoriasis who may benefit from injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light). It was recently approved in the US and several other countries for treatment of active psoriatic arthritis. TREMFYA is an example of Janssen’s pathways-centric strategy to fully develop compounds for multiple diseases.
PRODUCT: Rybelsus®

COMPANY: Novo Nordisk

THERAPEUTIC AREA & INDICATION:
GLP-1 agonist treatment to control blood sugar in adults with Type-II diabetes

ABOUT THE PRODUCT

Rybelsus® is the first and only glucagon-like peptide-1 receptor agonist (GLP-1RA) available as a tablet for the management of type 2 diabetes (T2D). Injectable GLP-1RAs are effective treatments for improving glycemic control and reducing body weight. Novo Nordisk has overcome the barriers to oral peptide delivery with a unique combination of semaglutide and a carrier molecule. Rybelsus® has been studied in >9,500 patients with T2D, and provided better glycemic control than all comparators in the phase 3 PIONEER program. Delivering peptide therapeutics orally opens up earlier and broader clinical use of GLP-1 RAs, and sets new standards for treatment of T2D.
**PRODUCT:** Dupixent® (dupilumab)

**COMPANY:** Regeneron and Sanofi

**THERAPEUTIC AREA & INDICATION:**
Single dose pre-filled pen technology to treat adults and adolescents with atopic dermatitis (eczema), asthma and rhinosinusitis with nasal polyposis

---

**ABOUT THE PRODUCT**

Dupixent is a biologic currently approved in the U.S., Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis as well as certain patients with asthma or chronic rhinosinusitis with nasal polyposis (CRSwNP) in different age populations. Excessive type 2 inflammation is an over-active immune response that can contribute to diseases like atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis. For decades, scientists have evaluated ways to inhibit the biologic pathways that underlie these types of diseases. Dupixent® (dupilumab) is the first fully human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a major role in type 2 inflammation. Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation.